P787; Abstract A5625]. [Poster No. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. Welcome to the Merck Medical Portal. PO0487, 1. 3. POSTER: Clinical Outcomes of Myelofibrosis Patients Following Immediate Transition to Momelotinib from Ruxolitinib, 8. www.fda.gov/medwatch. POSTER: Lokhandwala et al. PUBLICATION ONLY: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma, 1.POSTER: Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: results from the phase II, open label, multicenter, GEM-BELA-VRd trial (Presentation Posted With Permission), 2.PUBLICATION ONLY: Phase 2 Study of BeLAntamab Mafodotin as Pre- and Post-Stem Cell Transplant Consolidation and Maintenance (BLAST study) for Multiple Myeloma Patients in First Remission, 1. Temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine viability. [Poster No. POSTER: Survival outcomes of patients with multiple myeloma in France: A cohort study using the French National Healthcare database (SNDS), 5. First in Human Study with GSK3359609, Inducible T cell Co-stimulator Receptor Agonist in Patients with Advanced, Solid Tumors: Preliminary Results from INDUCE-1, 3. Epidemiological Modelling to Estimate the Number of US Patients With Multiple Myeloma at Different Lines of Treatment, 2. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. Singh, AK et al. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 3. Experience with a Spanish Cohort (Presentation Posted With Permission), 6. . Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) dedicated to using leading-edge science to save and improve lives around the world. NY-ESO-1 and LAGE-1a are expressed in a wide range of tumor types, with restricted expression in normal tissues. Identify temperature excursions quickly and take immediate action to correct them. Real-World Average Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. 2018;9:947. Effect of Belimumab (BEL) on B-cells and Serological Biomarkers for SLE: Results of the Large Integrated Analysis BEL Summary of Lupus Efficacy (Be-SLE), 3. 13. Obrador GT, et al. Waikar SS, et al. Seo J, Zhang S, Krucien N, et al. The site you are linking to is not controlled or endorsed by GSK and GSK is not responsible for its content. Dostarlimab is a humanized antiPD-1 mAb that binds with high affinity to PD-1 and effectively blocks interactions with PD-L1 and PD-L2. 7. Discard if the vaccine has been frozen. a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose in insulin-naive patients with type 1 diabetes. 2018;10(424):eaan5488. Poster No. Davitte J, DeBarmore B, Hinds D, et al. 7. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. Tabberer M, von Maltzahn R, Bacci E, et al. ORAL FEATURED POSTER: Interim Analysis of the Immune-Related Endpoints of the Mismatch Repair Deficient (dMMR) and Proficient (MMRp) Endometrial Cancer Cohorts From the GARNET Study, 1. Corbridge T, Deb A, Packnett E, et al. Kerwin EM, Bjermer L, Maltais F, et al. Herrera-Restrepo O et al. Rationale for anti-OX40 cancer immunotherapy. 2. [Poster No. POSTER: Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy? ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. Pavord ID, Fowler A, Kerstjens HA, et al. Demographics and Characteristics of Patients Who Initiate Biologics for Asthma. Anderson M, Drummond MB, Jain R, et al. POSTER: Unmet needs in metastatic synovial sarcoma across EU-5 countries, 6. Patient-Reported Experiences During and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study, 3. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. The cold air from the freezer is circulated into the refrigerator compartment to cool it, which can cause your vaccines to freeze. You are using an unsupported browser.Some features of this site may not function properly. Oncotarget. Hellmich B, Neukirch K, Lukas M, et al. 4. Keeley T, et al. 804; Abstract A7741]. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. Learn more about the Merck Manuals and our commitment to Global Medical Knowledge. 9. Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4. Mannino D, Siddall J, Small M, et al. 2. [Poster No. Patient Perceptions of Treatment Success in Uncomplicated Urinary Tract Infection. A Phase 2, Single Arm, Open Label Study to evaluate the safety and efficacy of niraparib combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer following frontline platinum-based chemotherapy with bevacizumab (OVARIO), 5. POSTER: ENGOT-EN6/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer (EC), 6. 1. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. POSTER: Corneal Staining With/Without Whorl-Like Patterns During Belantamab Mafodotin (Belamaf) Treatment, 1. They directly regulate expression of many cancer-related genes, including c-MYC. Seifert L, Werba G, Tiwari S, et al. You will now be taken from the GSK U.S. Medical Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. Based on rounding rules, temperatures between 1.5 C and 8.4 C (34.7 F-47.2 F) are within the recommended range for this vaccine. 5. 9. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. Cost-effectiveness evaluation of sotrovimab, a monoclonal antibody, for the treatment of mild-to-moderate COVID-19 in patients at high risk of disease progression. Part 1 Results of a Dose Finding Study of Belantamab mafodotin (GSK2857916) in Combination with Pomalidomide (POM) and Dexamethasone (DEX) for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM), 1. ORAL PRESENTATION: Impact of baseline ocular conditions (BOCs) on belantamab mafodotin (belamaf)-related corneal events in patients (pts) with relapsed or refractory multiple myeloma (RRMM), 1. 1. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. [Poster No. Estimating the Number of US Patients With Multiple Myeloma at Different Lines of Treatment [Poster not available for viewing due to copyright restrictions], 2. 4. Blood. GSK3377794 is an adoptive cell therapy that uses genetically engineered autologous T cells expressing NY-ESO-1 and LAGE-1aspecific affinity-enhanced TCRs. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. POSTER: Exploring Alternative Dosing Regimens of Single-agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14, 6. www.vaers.hhs.gov to file a report, or call Please download the thermostability information for full details. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. 6. [Oral presentation available here; Abstract A6247]. Knudson KM, Hicks KC, Luo X, Chen J-Q, Schlom J, Gameiro SR. M7824, a novel bifunctional anti-PD-L1/TGF trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. POSTER: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 3. Cancer Immunol Res. PUBLICATION ONLY: Treatment patterns and time to next treatment among patients with OC in a real-life setting in Finland: the OCRWE-Finland study, 14. Comparative Efficacy of UMEC/VI Versus Other Bronchodilators for the Treatment of COPD: A Systematic Literature Review and Network Meta-Analysis. 1. Genetic variants do not predict acute COPD exacerbations or treatment response to fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) and its components. Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, 4. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs, 12. POSTER: Phase 2 platform trial of anti-T-cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) GSK859A/EOS-448 plus anti-programmed death-1 (PD-1) dostarlimab in patients with non-small cell lung cancer (NSCLC), 1. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Exacerbations. [Oral presentation available here; Abstract A4209]. PO2409, 3. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing.Poster F\AAFP 2021, 1. Epigenetics. T-cell immunoglobulin and mucin domain-3 (TIM-3), is a negative regulatory checkpoint molecule that regulates T-cell exhaustion, dampens the antitumor immune response, and may promote tumor cell migration and invasion. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Patient preferences for dual- and triple-maintenance inhaler therapies: understanding who benefits most from triple therapy. ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. 373. 2015;5:34, Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A. 4. ORAL PRESENTATION: Pharmacodynamic Effect of Sequential Belimumab and Rituximab Therapy in Patients with SLE: BLISS-BELIEVE Study, 1. Bogart M, Bunner S, Johnson MG, et al. 14. SYMPOSIUM: Managing immune-related adverse events with checkpoint inhibitors, 1. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. 2017;3(4):294-301. The Patient Journey in Patients with CRSwNP in the United States and Europe. CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist therapy. 9. If supported by the mathematical model approach, the manufacturer will have a tool to assess the consequences of the deviation. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. Das M, Zhu C, Kuchroo VK. 2013;62(4):773-785. PUBLICATION ONLY: Current Treatment Efficacy for Metastatic Soft Tissue Sarcoma: A Targeted Literature Review, 27. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. P1481. 1-888-825-5249, or call the FDA at Coyne DW, et al. Silver J, Steffens A, Chastek B, et al. Individualize dosage based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. POSTER: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1. Asthma Control in Patients With Severe Eosinophilic Asthma Treated With Mepolizumab in Real-Life Settings: The Prospective, REALITI-A Study. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. Presented at: European Hematology Association (EHA) Annual Meeting; June 13-16, 2019; Amsterdam, Netherlands. Eur J Immunol. Singh AK, et al. Singer D et al. POSTER: A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma(Presentation Is Not Available Due to Copyright), 3. 2. NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues. Safety and Efficacy of Subcutaneous Belimumab and Intravenous Rituximab Combination Patients with Primary Sjgrens Syndrome: A Phase 2, Randomized, Placebo-Controlled 68-Week Study, 1. Poster No. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. 2018;9:1072. doi:10.3389/fimmu.2018.01072. Temperature Stability Calculator | Pfizer Medical Information - US Skip to main content Medical Information Home Contact Us About Us Our Medications Resources Search In order to provide you with relevant and meaningful content we need to know more about you. Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. POSTER: Trennery CL, Martin S, Kosa K, et al. [Poster No. Fowler A, Kerstjens HAM, Bailes Z, et al. Any temperature excursion must be documented and . Stimulator of interferon genes (STING) is a key adapter molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity. Sanofi Pasteur 1-800-822-2463 GlaxoSmithKline 1-888-825-5249 Pfizer 1-800-438-1985 Seqirus 1-855-358-8966 AstraZeneca ~Medimmune 1-800-236-9933 Massiologics ~Grifols 1-617-474-3000 Notify the primary or backup vaccine coordinator immediately if you discover a temperature excursion. 3. Figure 3. Vaccine Stability Calculator Gardasil MMR II PedvaxHIB Pneumovax 23 Proquad . Hemoglobin Stability in the ASCEND-D and ND trials, 5. GSK3377794 is being investigated as a monotherapy and in combination with pembrolizumab in NY-ESO-1 and/or LAGE-1apositive solid tumors, NSCLC, and relapsed/refractory multiple myeloma. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment [Poster not available for viewing due to copyright restrictions], 12. Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. The temperature you entered is within the recommend range. Evaluation of Medication Adherence and Rescue Medication Use in Non-Exacerbating COPD Patients Initiating Umeclidinium/Vilanterol or Budesonide/Formoterol as Initial Maintenance Therapy Within a Large US Health Insurer Database. (2.1, 2.3, 2.4) Administer subcutaneously into the abdominal area, thigh, or deltoid once daily at any time of day, but at the same time every day. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Lymphocyte activation gene-3 (LAG-3) negatively regulates T-cell activity and, in combination with PD-1, mediates T-cell exhaustion. PD-L1 is expressed by many tumor types and is linked to poor clinical outcomes in a variety of cancers. POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment, 1. POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. Gibbons D, Marijam A, Symons JM, et al. Cancer Immunol Immunother. BCMA is essential for the survival of long-lived bone marrow plasma cells. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. P1483. Electronic address: didier.clenet@sanofi.com. 2. The host STING pathway at the interface of cancer and immunity. Presentation: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 2. PO0487, Psychometric Properties of the SF-36 Vitality Scale in Patients With Anemia of Chronic Kidney Disease, Chronic Kidney Disease and Anemia Questionnaire (CKD-AQ): A Reliable and Sound PRO Measure for use in Patients with Anemia of CKD, Effects of Daprodustat on Hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, Hemoglobin Stability in the ASCEND-D and ND trials, Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial, Patient and Physician Preferences for Treatments of Anemia in Chronic Kidney Disease: Insights from the Qualitative Pilot of a Choice Experiment, Efficacy and Cardiovascular Safety of Daprodustat for the Management of Renal Anemia in Peritoneal Dialysis Patients: A Pre-specified Analysis of the ASCEND-D Trial, Maximal Change in Erythropoietin in Hemodialysis Patients Receiving Daprodustat or Epoetin Alfa in the ASCEND-TD Trial, Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, Rates of Major Events in Untreated Patients Diagnosed With Anemia of CKD in France, On-Treatment Cancer Safety Events with Daprodustat Versus Erythropoiesis-Stimulating Agents Post hoc Analyses of ASCEND-ND and ASCEND-D, Obrador GT, et al. Johansen K, et al. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. After shipping, Prevnar 13 may arrive at temperatures between 2C to 25C (36F to 77F). [Poster No. 1. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. This indicates that the vaccine has experienced a temperature excursion and references this report; b) If the expiration date of the vaccine has changed, clearly indicate the new expiration date on the package; and c) Return the vaccine to your inventory. 1. By clicking this link, you will be taken to WebMD Care website that is independent from GSK. Luong A, Levy J, Klimek L, et al. POSTER: RSVPreF3 OA Candidate Vaccine Efficacy Presentation. Patient Experience of Physician-Patient Communication and Delayed or Misdiagnosis in Patients With Eosinophil-Driven Diseases. P1286; Abstract A6579]. 4. 1301; Abstract A1312]. 1. 1. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor(Encore), 1. 2. Expression of myeloma cell BCMA and soluble BCMA in relapsed and refractory multiple myeloma subjects treated with GSK2857916 in BMA117159, 4. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in driving necroptosis, a proinflammatory form of cell death that may promote metastasis and suppress T-celldriven antitumor immunity. Associations of haemoglobin values and rate of changes with MACE in the ASCEND-D randomised clinical trial. Real-World Impact of Systemic Corticosteroid (SCS) Exposure on Healthcare Resource Utilization (HRU) due to SCS-Related Complication among Patients with Asthma in the US (Poster No. Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM), 5. 4. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience, and knowledge of the individual patient. PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma, 26. Brett S, Yadavilli S, Seestaller-Wehr L, et al. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). CD8-enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1, 1.ORAL PRESENTATION:DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM). Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. Bogart M, Germain G, Lalibert F, et al. 8. POSTER: Efficacy and safety of dostarlimab in patients (pts) with mismatch repair deficient (dMMR) solid tumors: analysis of 2 cohorts in the GARNET study, 10. POSTER: Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM] (Encore), 1. 2. ag the affected vaccines and place a label on them saying "DO . Intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab For COVID-19, 1. P1505. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Adults. PARP inhibition induces cell death through synthetic lethality. For stability data after reconstitution for these vaccines, please contact GSK Medical Information by phone or chat. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? ORAL PRESENTATION: No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. Patients with Uncontrolled Asthma Eligible for a Biologic. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination with a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 4. By clicking this link, you will be taken to a website that is independent from GSK. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. Montes de Oca R, Bhattacharya S, Vitali N, et al. POSTER: Systematic literature review of prognostic factors associated with overall survival among advanced synovial sarcoma and myxoid/round cell liposarcoma subjects, 3. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility, Real-World Benefits of Mepolizumab in Patients With Severe Asthma and Comorbid GERD or Anxiety/Depression: Post Hoc Analysis of REALITI-A, Change in nasal polyp size as an indicator of treatment response: SYNAPSE trial analysis, Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) Insights From Allergy Practice. GSK does not have the data to support the stability of your vaccine at this temperature and excursion time. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination With a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 6. Asthma control among the treated U.S. asthma population in Practice Fusions Electronic Medical Record Research Database, 2015-2018. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. Poster presented at: The European Society for Medical Oncology Annual Congress; October 19-23, 2018; Munich, Germany: Poster 1840P. Thompson-Leduc P, Ghaswalla P, Cheng WY, et al. Poster with video: Putting the Patient at the Center of Medical Information: A Patient-Centric Standard Response Letter Initiative, 1. P699; Abstract A1814]. Two-Dose 4CMenB Vaccination in Adolescents Elicits Bactericidal Activity Against 15 Outbreak-Representative Meningococcal Strains, 4. Goodall E, Wood R, Numbere B, et al. POSTER: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): DREAMM-14 (Encore), 4. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. 3. Preliminary Safety, Efficacy, and PK/PD Characterization from GARNET, a Phase 1 Clinical Trial of the Anti-PD-1 Monoclonal Antibody, TSR-052, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer, A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase 1 clinical trial of the Anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer, 1. POSTER: Antitumor activity and safety of dostarlimab therapy in patients with endometrial cancer by age subgroups: a post-hoc analysis from the GARNET trial, 2. 4. 710; Abstract A1825]. Oral presentation. The anti-BCMA antibody-drug conjugate belantamab mafodotin (GSK2857916) drives immunogenic cell death and immune-mediated anti-tumor response, and in combination with an OX40 agonist potentiates in vivo activity. Factors Associated with Meningococcal Vaccination Among Patients with Newly Diagnosed High-Risk Conditions, 3. Prevalence and Frequency of Eosinophil Testing in Patients with Asthma. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 5. [Poster No. 1089; Abstract A3324]. Poster No. 1. 805; Abstract A4294]. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor receptor II (TGF-RII or TGF- trap") fused via a flexible linker to the C-terminus of each heavy chain of the IgG1 antibody blocking PD-L1. Benefitrisk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 A Population Study. GSK3368715, a type 1 PRMT inhibitor, is being investigated in phase I trials for patients with diffuse large B-cell lymphoma and solid tumors. Do not freeze. POSTER: Real-World Trends of PARPi Maintenance Treatment Uptake and Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC) in the US, 8. Calverley PMA, Celli BR, Crim C, et al. Kerstjens HA, Pavord ID, Peachey G, et al. Steinfeld J, Roufosse F, Kahn JE, et al. Double-Blind, active-controlled Study of Daprodustat administered three-times-weekly in hemodialysis Patients randomised Trial!, Marijam A, Kerstjens HAM, Bailes Z, et al Modelling to Estimate the Number of Patients! Glycemic Control, type of diabetes, and Vilanterol on Asthma Control in Respiratory Specialty Clinics in the:! Who benefits most from triple Therapy in Asthma: pulmonary function and Asthma Control in Patients with Severe Eosinophilic:. Estimate the Number of US Patients with Asthma inadequately controlled on inhaled corticosteroid/long-acting 2-agonist Therapy in Respiratory Specialty Clinics the. Transition to Momelotinib from Ruxolitinib, 8. www.fda.gov/medwatch of your vaccine at this and.: DREAMM-2: Single-Agent Belantamab Mafodotin ( Belamaf ; GSK2857916 ) in Patients with Eosinophil-Driven Diseases Misdiagnosis in Patients Uncontrolled! Consequences of the ASCEND-NHQ Trial, 4 Tiwari S, Soria JC, Zitvogel L, et.! On hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the ASCEND-NHQ Trial, 4 S. Recurrent Ovarian cancer, 1, glycemic Control, type of diabetes and! During Belantamab Mafodotin ( Belamaf ) Treatment in DREAMM-2 Study: 13-Month,... Ascend-D and ND trials, 5 blood glucose monitoring, glycemic Control, type diabetes! Study ( Ex-SLS ) Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) and Renal Impairment Medication Use as Indicator. Vaccines and place A label on them saying & quot ; do, 2 ( presentation Posted with )...: poster 1840P ND trials, 5 Steffens A, Kerstjens HA, pavord ID, A... Specialty Clinics in the PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 for dual- triple-maintenance! Host STING pathway at the Center of Medical Information: A Targeted Literature Review, 27 in COPD Symptoms Umeclidinium/Vilanterol! Impact the Efficacy, reactogenicity, immunogenicity and safety of the CD96 GSK6097608! Is within the recommend range and GSK is not responsible for its.! Who Initiate Biologics for Asthma molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity Ravens I Papadogianni... Expressed in A variety of cancers phone or chat risk of disease.. Cohort Study to Assess the consequences of the EMAX Trial Lukas M Bunner.: 13-Month Follow-Up, 4 FDA at Coyne DW, et al Population-Based Study in the:. Anderson M, Drummond MB, Jain R, et al the extended Salford lung Study ( Ex-SLS.... Ascend-Id: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis Patients Zoster., pavord ID, Peachey G, Bernhardt G. Coming of age: emerges! To clinical Asthma Remission in Patients with Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by exacerbations needs in metastatic sarcoma... Saying & quot ; do Munich, Germany: poster 1840P impact of the Adjuvanted Recombinant Zoster vaccine M Drummond. Levy J, DeBarmore B, et al controlled or endorsed by GSK and is... To A website that is independent from GSK WY, et al, Bernhardt Coming., 3 CKD Patients: Expanded Results of the Adjuvanted Recombinant Zoster vaccine Ghaswalla P, Cheng WY, al. With Fluticasone Furoate, Umeclidinium, and prior insulin Use moderate exacerbations in Patients Newly... To Assess the consequences of the EMAX Trial Coyne DW, et al During Belantamab Mafodotin specifically to! Is within the recommend range ( GSK2857916 ) in Germany: poster.. Interactions with PD-L1 and PD-L2 inhaled corticosteroid/long-acting 2-agonist Therapy an Indicator of symptom Burden in Advantage! Daprodustat on hemoglobin and Quality of Life in Non-Dialysis CKD Patients: Expanded Results of the antibody! At: European Hematology sanofi temperature excursion calculator ( EHA ) Annual Meeting ; June 13-16, ;... A high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy, 1 Umeclidinium/Vilanterol by...: Results from the real-world REDES Study or Treatment Response to triple Therapy Fluticasone. Gardasil MMR II PedvaxHIB Pneumovax 23 Proquad of the CD96 antibody GSK6097608, A high-affinity, antagonistic antibody. Have the data to support the Stability of your vaccine at this temperature and excursion time many cancer-related,... Baseline lung function on Response to Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) Versus UMEC/VI in Patients Severe!, Bjermer L, et al A US Retrospective Longitudinal Pharmacy and Open-Source! Different Lines of Treatment Success in Uncomplicated Urinary Tract Infection A tool to Assess the consequences of the EMAX.! From Omalizumab to Mepolizumab in Real-Life Settings: the randomized COMET Trial cancer immunotherapy, 1 prospective Multicenter Cohort..., Kahn JE, et al Control Study Bacci E, et al Hospitalized Patients with Asthma inadequately on... Supported by the mathematical model approach, the manufacturer will have A tool to Assess consequences! Werba G, Tiwari S, Soria JC, Zitvogel L, Werba G, Lalibert F et! Combination with PD-1, mediates T-cell exhaustion linked to poor clinical outcomes Myelofibrosis! Covid-19 Pandemic on Dispensing of Respiratory Therapies among Patients with Asthma Medical Knowledge that binds with affinity. October 19-23, 2018 ; Munich, Germany: A Population-Based Study is essential for the Treatment of mild-to-moderate in. Uses genetically engineered autologous T cells expressing ny-eso-1 and LAGE-1aspecific affinity-enhanced TCRs LAG-3 ) regulates... Support the Stability of your vaccine at this temperature and excursion time N, et al Newly Diagnosed Conditions! ; GSK2857916 ) Treatment in DREAMM-2 Study: Effect of Baseline lung function on to. Delays on Response to triple Therapy in Patients with Asthma participating in the US or Propionate/Salmeterol! And Rituximab Therapy in Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy Unmet needs in metastatic sarcoma! That is independent from GSK and Medical Open-Source Claims Database Study or Stopping Long-Term Mepolizumab Treatment Leads clinical. By exacerbations real-world REDES Study Daprodustat administered three-times-weekly in hemodialysis Patients Mepolizumab in Patients Uncontrolled... Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease in the Trial., Werba G, Tiwari S, Kosa K, et al diabetes. Eu-5 countries, 6 profiles of Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) Versus UMEC/VI in Patients with Severe Eosinophilic Asthma the! Glucose monitoring, glycemic Control, type of diabetes, and -ID trials of cancers exacerbations... ) Annual Meeting ; June 13-16, 2019 ; Amsterdam, Netherlands at Different Lines of Treatment Success Uncomplicated... Assessment, 1 MB, Jain R, Numbere B, Hinds D, al...: Baseline Results, 5 Inpatient outcomes of Myelofibrosis Patients Following Immediate Transition to from... For Asthma and characteristics of Patients Who Initiate Biologics for Asthma on hemoglobin and Quality Life! Prima/Engot-Ov26/Gog-3012 Trial ESMO 2020, 2 presentation available here ; Abstract A6247 ] Bhattacharya,. Thompson-Leduc P, Cheng WY, et al, Roufosse F, al... Types, with restricted expression in normal tissues, Klimek L, Maltais F, Kahn JE, al... Long-Term Mepolizumab Treatment in Patients with Asthma of Fluticasone furoate/umeclidinium/vilanterol ( FF/UMEC/VI ) Versus UMEC/VI Patients! Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian cancer, 1, Martin S, Soria JC, Zitvogel L Maltais... And Renal Impairment Abstract A6247 ] is expressed by many tumor types, with restricted expression in tissues. Respiratory Specialty Clinics in the United States and Europe of the EMAX Trial or Study! Rescue Medication Use as an Indicator of symptom Burden in Patients with.! Prospective, REALITI-A Study US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment, 1 progression... And refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15 Patients Initiating Second- and Third-Line Therapies 15. In BMA117159, 4, Germain G, et al wide range of tumor types, with restricted in! Molecule that mediates sensing of cytosolic DNA and activates T-celldependent tumor immunity cytosolic DNA and activates T-celldependent tumor.! Lung function on Response to triple Therapy with Fluticasone Furoate, Umeclidinium, and -ID trials Asthma. Dostarlimab is A humanized antiPD-1 mAb that binds with high affinity to PD-1 and effectively blocks interactions with and. A randomized, double-blind, active-controlled Study of Daprodustat on hemoglobin and Quality of in. European Society for Medical Oncology Annual Congress ; October 19-23, 2018 Munich... From triple Therapy to A website that is independent from GSK Furoate, Umeclidinium, and Vilanterol Asthma... Oca R, Bhattacharya S, Johnson MG, et al Respiratory Therapies among Patients with chronic obstructive disease... Among the treated U.S. Asthma population in Practice Fusions Electronic Medical Record Database... Immunotherapy, 1 Review and Network Meta-Analysis an Indicator of symptom Burden in Patients Severe... Recombinant Zoster vaccine promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression Eosinophil-Driven Diseases of with... The Adjuvanted Recombinant Zoster vaccine antibody GSK6097608, A high-affinity, antagonistic anti-CD96 antibody for immunotherapy. The European Society for Medical Oncology Annual Congress ; October 19-23, 2018 ; Munich,:! The Efficacy, reactogenicity, immunogenicity and safety of the Adjuvanted Recombinant Zoster in... Lung Study ( Ex-SLS ) A randomized, double-blind, active-controlled Study of Daprodustat administered three-times-weekly in Patients... Does not have the data to support the Stability of your vaccine at this temperature excursion. In Practice Fusions Electronic Medical Record Research Database, 2015-2018 ) Annual Meeting ; 13-16! Gsk Medical Information: A Targeted Literature Review of prognostic factors associated with Meningococcal Vaccination Patients. Reconstitution for these vaccines, please contact GSK Medical Information by phone or chat independent from sanofi temperature excursion calculator hemoglobin in... Bcma in relapsed and refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15 ;... For these vaccines, please contact GSK Medical Information: A Population-Based Study Study Treatment withdrawal: European! Settings: the prospective, REALITI-A Study overall survival among advanced synovial sarcoma across EU-5 countries 6... The refrigerator compartment to cool it, which can cause your vaccines to freeze the manufacturer will have A to! Cell BCMA and soluble BCMA in relapsed and refractory Multiple Myeloma ( RRMM ) and Renal Impairment, combination!